 |
| U.S. oncology based in-vivo CRO market, by indication, 2014 - 2025 (USD Million) |
The global oncologybased in-vivo CRO market is expected to reach USD 1.5 billion by 2025, according to a new report by Grand View Research, Inc. The use of Contract Research Organization (CRO) oncology services helps the manufacturers/sponsors to provide complete attention on the production capacity and at enhancing their in-house processes.
Furthermore,
the pressure from the increasing competition due to patent expirations, rapid
growth of generics, and introduction of biosimilar equivalents are propelling
the pharmaceutical companies to take the aid of such organizations. Hence, it
can be predicted that the oncology based in-vivo CRO
market may witness lucrative growth over the forecast period.
Another factor propelling growth is the
increasing incidence of cancer, and high failure rate of existing treatment
options. According to statistics published by the World Health Organization
(WHO), approximately 8.2 million deaths are recorded each year from cancer,
which accounts for 13.0% deaths worldwide.
Full Research Report On Oncology Based In-Vivo CRO
Market Analysis:
Further key findings from the study suggest:
·
Based on indication, solid tumors are
expected to dominate the market as of 2016. Furthermore, it is anticipated to
grow at the fastest CAGR owing to the factors such as growing incidence rate,
augmenting research for tumors in organs such as breast, and liver, and
technological advancement offered by key industry players.
·
Solid tumors are analyzed by means of
models such as xenograft, Patient Derived Xenografts (PDX), and syngeneic. The
PDX models are expected to witness lucrative growth over the forecast period
and capture over 40.0% of the market share by 2025.
·
Geographic expansion into Asia Pacific
countries by well-established players is anticipated to promote the fastest
growth for the region. India is one the most lucrative country owing to
presence of service tax exemption and venture capital based funding for CROs.
·
Few of the industry players for the
oncology based in-vivo CRO market are The Jackson
Laboratory, Covance, Taconic Biosciences, Charles River Laboratory, EVOTEC,
Wuxi AppTec, and ICON Plc.
·
A common trend observed is the rising
partnerships among CROs to offer bundle packages of services to sponsors. For
instance, In May 2017, CRL International, Inc. announced their partnership with
OcellO, established in Netherlands. According to this partnership, CRL would be
utilizing the latter’s PDX model capabilities in order to expand their oncology
based drug discovery service portfolio.
Browse More Reports Of This Category By
Grand View Research At: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research
has segmented the global oncology based in-vivo CRO
market on the basis of indication, and region:
Global Oncology Product Outlook (Revenue,
USD Million, 2014 - 2025)
·
Blood cancer
·
Solid tumors
o
Syngeneic model
o
Patient Derived Xenograft (PDX)
o
Xenograft
·
Others
Oncology in-vivo CRO Regional Outlook (Revenue,
USD Million, 2014 - 2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
UK
o
Germany
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
o
Argentina
·
Middle East and Africa (MEA)
o
South Africa
o
Saudi Arabia
Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-oncology-based-in-vivo-cro-market
www.grandviewresearch.com/press-release/global-oncology-based-in-vivo-cro-market
About Grand
View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com
No comments:
Post a Comment